Navigation Links
Dalton Pharma Services and ProCitius Announce a Strategic Alliance to Provide Contract Chemistry Services
Date:5/11/2009

TORONTO, and CHENNAI, India, May 11 /PRNewswire/ -- Dalton Pharma Services and ProCitius Research jointly announce a strategic alliance created to provide clients with contract chemistry services of exceptional value.

Global pharmaceutical companies, in order to maintain their discovery and development output in an era of severe cost restraints, have been increasing their use of "offshore" contract research organizations (CROs) in countries such as China and India. Despite the quality of chemists in offshore CROs, there are often performance issues caused by communication and cultural differences. In order to ensure quality and timeliness in the contracted work, pharmaceutical companies are usually forced to dedicate senior staff to manage these projects on-site or from Western research centers.

Dalton and ProCitius have teamed up to offer clients the best of both worlds. Projects carried out by ProCitius in India are tightly controlled by senior Dalton project managers based at the company headquarters in Canada. Clients deal only with Dalton, which assumes full legal and operational responsibility for the satisfactory execution of the contract. The contract pricing is based on attractive FTE rates.

"I believe this type of hybrid service fills an important need in our industry," said Peter Pekos, President and CEO of Dalton Pharma Services. "Over the past two decades I have worked to adjust our service offering to meet the changing requirements of my clients and today's announcement is part of this continuing evolution," he continued. "In ProCitius we have the ideal partner: well-established; large FTE headcount; excellent facilities and infrastructure; robust documentation; and a reputation for high ethical and environmental standards."

Jeri Raman, VP Business Development of ProCitius Research, remarked, "We are extremely pleased to have established this strategic alliance with Dalton Pharma Services. The reputation of Dalton as a premium CRO in the areas of chemistry and medicinal chemistry makes it the perfect choice for the expansion of our business with the global pharmaceutical industry."

About Dalton Pharma Services

Dalton Chemical Laboratories Inc. o/a Dalton Pharma Services is a Health Canada approved contract pharmaceutical manufacturer that supplies chemistry, medicinal chemistry and analytical services to the biotechnology and pharmaceutical industries in the areas of chemistry, medicinal chemistry, fine chemical manufacture, custom peptides and antisense oligo production. Dalton provides cGMP manufacturing and sterile filling services to its customers at any stage of the regulatory process (Phase I, II, III or commercial). In its state of the art cGMP facilities, Dalton can produce active pharmaceutical ingredients (API), at the gram or kilogram scale. Dalton can carry out sterile fills to produce batches of finished drug product in vials or syringes, either aseptically filled or terminally sterilized, under fully validated conditions. In addition, Dalton's analytical chemistry laboratory offers method development, validation and ICH stability programs to its clients.

About ProCitius Research, a division of Sanmar Speciality Chemicals Ltd.

Sanmar Speciality Chemicals is a member of the Sanmar Group, one of India's most respected business houses. Through its research arm, ProCitius Research, with its state-of-the-art facilities, it offers world class services in contract research and custom synthesis. It has an impressive track record with major pharmaceutical and chemical manufacturers in Europe and the United States of America. More information about the capabilities of Sanmar Speciality Chemicals can be obtained at the website, www.sanmargroup.com/SSCLmain.htm.

    Contact:
    Dalton Pharma Services
    Peter Pekos
    416-661-2102
    ppekos@dalton.com
    www.dalton.com


    Contact:
    ProCitius Research
    Dr. Bhuvaneswari Sridhar
    91-44-4225-3080
    bs8@sanmargroup.com
    www.sanmargroup.com


'/>"/>
SOURCE Dalton Pharma Services
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. BioRelix and Dalton Medicinal Chemistry Expand and Renew Research Agreement to Capitalize on Riboswitches
2. Dalton Pharma Services Licenses Thermo Fisher Scientific Technology to Produce Polynucleotides for Drug Development
3. BIKAM and Dalton Medicinal Chemistry Sign Collaborative Research Agreement
4. Dalton Medicinal Chemistry Partners Achieves Another Milestone in Collaboration with Boehringer Ingelheim (Canada) Ltd.
5. BioRelix and Dalton Medicinal Chemistry Sign Research Agreement to Capitalize on RiboSwitch Technology
6. Dalton Medicinal Chemistry Partners Achieves Milestone in Collaboration with Boehringer Ingelheim (Canada) Ltd.
7. Pharmaceutical Packaging Equipment Manufacturer Boosts European Distribution
8. PharmAthene Announces New Date for First Quarter 2009 Conference Call and Webcast
9. Cadence Pharmaceuticals Reports First Quarter 2009 Financial Results
10. PDL BioPharma Announces First Quarter 2009 Financial Results
11. Rib-X Pharmaceuticals Announces Presentations at the 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... Franz ... Lisp (CL) development tools, and market leader for Semantic Graph Database ... now available within the most effective system for developing and deploying applications to ...
(Date:4/25/2017)... ... ... Leaders of Quorum Review IRB and Kinetiq , the consulting ... Association of Clinical Research Professionals (ACRP) 2017 Meeting & Expo with topics ... excited to present subject matter expertise on topics that impact the global clinical research ...
(Date:4/21/2017)... , ... April 21, 2017 , ... ... Webster Bank, today announced first round funding to three startups through the UConn ... financial support to new business startups affiliated with UConn. , The UConn Innovation ...
(Date:4/20/2017)... ... April 20, 2017 , ... As ... webinar will explore challenging patient cases when screening for direct oral anticoagulant. When ... be a need for bridging parental anticoagulation especially for those at high risk ...
Breaking Biology Technology:
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
(Date:3/29/2017)... , March 29, 2017  higi, the health IT ... North America , today announced a ... the acquisition of EveryMove. The new investment and acquisition ... of tools to transform population health activities through the ... data. higi collects and secures data today ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... Industry Forecast to 2025" report to their offering. ... The Global Biometric Vehicle Access ... 15.1% over the next decade to reach approximately $1,580 million by ... and forecasts for all the given segments on global as well ...
Breaking Biology News(10 mins):